Adamax Dosage: Why No Dose Can Be Stated
Adamax dosage: only one vendor gives any figures, with no second source to check them against, and sellers disagree on what molecule is even being dosed.
The short version
This site states a common protocol only when at least two real sources, on different sites, agree on numbers. For Adamax, only one of the two vendor sources checked gives any dosing figures, and the two sources do not agree on what molecule "Adamax" is. No dose is stated here as a result. The disagreement itself is the finding.
- Only one of two vendor sources checked gives dosing figures. The other sells the substance with no dosing guidance.
- The single dosing source cites no trial, study or clinical basis for its own figures.
- The two sources describe structurally different molecules under the same name.
- No dose is stated on this site for Adamax as a result.
Adamax has no dose stated on this site. The number is not missing by oversight. The two real sources checked for it fail this site’s sourcing bar in two separate ways, detailed below. For what Adamax is marketed as and why its chemical identity is unresolved, see the main Adamax guide.
US legal status - Unapproved drug
Not FDA-approved for any indication. No DailyMed listing.
AU legal status - Not on the ARTG
Not reviewed by any Australian regulator this page could verify.
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
Why there is no common protocol here
This site states a dosing protocol only when at least two real sources, on different sites, were fetched, read, and agree on usable numbers. Two vendor sources were checked for Adamax:
| Source | What it offers |
|---|---|
| Biomogging (nootropic content site) | A detailed titration schedule - 200-300 mcg/day rising to 750-1,000 mcg/day over several weeks, subcutaneous or intranasal, 8-12 week cycles - with no trial, study or clinical source cited for any of it |
| BOC Sciences (chemical manufacturer) | Sells the raw peptide “for research and manufacturing use only,” explicitly states it does not sell to patients, and gives no dosing information whatsoever |
That leaves one source with any figures, and it cites nothing behind its numbers. This site’s bar requires two sources that agree. One uncorroborated figure does not meet it, however precise or official it looks on the page presenting it.
What is not established
- No dose, route, frequency or cycle length is established by any trial, regulator or corroborated source.
- No chemical identity is settled between the vendors selling it under this name.
- No published safety data exists to define a floor for who should avoid it or what a concerning reaction would look like.
Who should not use it
No FDA-reviewed contraindication list exists, because no such review has happened. There is also no trial population to draw even an informal floor from. Unlike most research compounds this site covers, there is no published human or animal study of Adamax to take exclusion criteria from.
Adamax side effects and risks
No published research of any kind (human, animal or in vitro) exists for Adamax, so there is no trial-reported or case-report safety data to summarise. Beyond that absence, this substance carries a risk most research chemicals on this site do not. Its own sellers describe two different molecules under the same name, so a buyer cannot know from the product name which structure, if either as described, a vial contains.
Get emergency care for signs of a severe allergic reaction (swelling of the face, lips, tongue or throat, or difficulty breathing). Get it too for any severe or rapidly worsening symptom after taking anything sold as Adamax.
Related
- Adamax: what it is and the identity problem
- Semax
- N-Acetyl-Semax-Selank
- Research peptides and the law
Where to buy Adamax for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
2.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
What is the usual Adamax dose?
This page does not state one. Site policy requires at least two real sources, on different sites, that agree on usable dosing numbers. Of the two vendor sources checked, only one (a nootropic content site) gives any dosing figures, and it cites no trial, study or clinical source for them. The other (a chemical manufacturer selling the raw substance) gives no dosing information. A single, uncorroborated figure is not a common protocol.
What dose does the one source with figures describe?
A nootropic-vendor site describes a titration schedule rising from 200-300 mcg per day to 750-1,000 mcg per day, by subcutaneous injection or intranasally, over several weeks, in 8-12 week cycles. The figure appears on one site only, with no cited trial, published study or clinical protocol behind it and no second source to check it against. It is reported here only to explain why it does not meet this site's bar for a stated protocol, not as usable dosing information.
Why not just report that one source's numbers?
This site's dosing pages depend on cross-checking at least two independent, real sources before stating a number, the same standard applied to every other research compound here. Making an exception for a single-sourced figure, for a compound whose chemical identity is disputed, would undermine that standard everywhere else.
Is there an FDA-approved Adamax dose?
No. Adamax is not FDA-approved for any indication and does not appear in DailyMed.
What are the main risks?
No published safety data of any kind exists for Adamax. Any unregulated research-chemical vial carries unverified content, purity and concentration. Adamax has a more basic risk: its sellers do not agree on what molecule is in the vial.